Neurobiology of Aging
Volume 29, Issue 3 , Pages 368-378 , March 2008

Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice

  • E. Machová

      Affiliations

    • Department of Neurochemistry, Institute of Physiology CAS, Vídeňská 1083, 14220 Prague 4, Czech Republic
    • ,
  • J. Jakubík

      Affiliations

    • Department of Neurochemistry, Institute of Physiology CAS, Vídeňská 1083, 14220 Prague 4, Czech Republic
    • ,
  • P. Michal

      Affiliations

    • Department of Neurochemistry, Institute of Physiology CAS, Vídeňská 1083, 14220 Prague 4, Czech Republic
    • ,
  • M. Oksman

      Affiliations

    • Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland
    • ,
  • H. Iivonen

      Affiliations

    • Department of Neurobiology, A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland
    • ,
  • H. Tanila

      Affiliations

    • Department of Neurobiology, A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland
    • Department of Neurology, Kuopio University Hospital, Kuopio, Finland
    • ,
  • V. Doležal

      Affiliations

    • Department of Neurochemistry, Institute of Physiology CAS, Vídeňská 1083, 14220 Prague 4, Czech Republic
    • Corresponding Author InformationCorresponding author. Tel.: +420 296442287; fax: +420 296442488.

Received 28 June 2006 ,Revised 20 September 2006 ,Accepted 30 October 2006.

References 

  1. Aucoin JS, Jiang P, Aznavour N, Tong XK, Buttini M, Descarries L, et al. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience. 2005;132:73–86
  2. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000;163:495–529
  3. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414
  4. Berrard S, Varoqui H, Cervini R, Israel M, Mallet J, Diebler MF. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter. J. Neurochem. 1995;65:939–942
  5. Berse B, Blusztajn JK. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J. Biol. Chem. 1995;270:22101–22104
  6. Blusztajn JK, Berse B. The cholinergic neuronal phenotype in Alzheimer's disease. Metab. Brain Dis. 2000;15:45–64
  7. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459–496
  8. Brandon EP, Mellott T, Pizzo DP, Coufal N, D’Amour KA, Gobeske K, et al. Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J. Neurosci. 2004;24:5459–5466
  9. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. U.S.A. 1992;89:10075–10078
  10. Capsoni S, Giannotta S, Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol. Cell Neurosci. 2002;21:15–28
  11. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2000;97:6826–6831
  12. Cervini R, Houhou L, Pradat PF, Bejanin S, Mallet J, Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 1995;270:24654–24657
  13. Custers FG, Leysen JE, Stoof JC, Herscheid JD. Vesamicol and some of its derivatives: questionable ligands for selectively labelling acetylcholine transporters in rat brain. Eur. J. Pharmacol. 1997;338:177–183
  14. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403
  15. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002;51:145–155
  16. Dolezal V, Kasparova J. Beta-amyloid and cholinergic neurons. Neurochem. Res. 2003;28:499–506
  17. Duysen EG, Stribley JA, Fry DL, Hinrichs SH, Lockridge O. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res. Dev. Brain Res. 2002;137:43–54
  18. Efange SM, Garland EM, Staley JK, Khare AB, Mash DC. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol. Aging. 1997;18:407–413
  19. Ellman GL, Courtney KD, Andres VJ, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961;7:88–95
  20. Erickson JD, Varoqui H, Schafer MK, Modi W, Diebler MF, Weihe E, et al. Functional identification of a vesicular acetylcholine transporter and its expression from a “cholinergic” gene locus. J. Biol. Chem. 1994;269:21929–21932
  21. Fonnum F. Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. Biochem. J. 1969;115:465–472
  22. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 1985;313:7–11
  23. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 1999;66:137–147
  24. Frolich L. The cholinergic pathology in Alzheimer's disease—discrepancies between clinical experience and pathophysiological findings. J. Neural. Transm. 2002;109:1003–1013
  25. Gau JT, Steinhilb ML, Kao TC, D’Amato CJ, Gaut JR, Frey KA, et al. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. 2002;160:731–738
  26. German DC, Yazdani U, Speciale SG, Pasbakhsh P, Games D, Liang CL. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 2003;462:371–381
  27. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A. 2005;102:17213–17218
  28. Haass C, Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders?. Nat. Neurosci. 2001;4:859–860
  29. Hartmann J, Erb C, Ebert U, Baumann KH, Popp A, Konig G, et al. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience. 2004;125:1009–1017
  30. Hedreen JC, Bacon SJ, Price DL. A modified histochemical technique to visualize acetylcholinesterase-containing axons. J. Histochem. Cytochem. 1985;33:134–140
  31. Holler T, Berse B, Cermak JM, Diebler MF, Blusztajn JK. Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Neurosci. Lett. 1996;212:107–110
  32. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 2000;35:1363–1372
  33. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102
  34. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience. 2003;121:421–432
  35. Ikarashi Y, Harigaya Y, Tomidokoro Y, Kanai M, Ikeda M, Matsubara E, et al. Decreased level of brain acetylcholine and memory disturbance in APPsw mice. Neurobiol. Aging. 2004;25:483–490
  36. Jakubik J, Bacakova L, el-Fakahany EE, Tucek S. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1–M5 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 1995;274:1077–1083
  37. Jakubik J, El-Fakahany EE, Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M1 and M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 2006;
  38. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 2005;25:5217–5224
  39. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159–170
  40. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157–165
  41. Jope RS, Song L, Li X, Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol. Aging. 1994;15:221–226
  42. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol. Aging. 1997;18:111–120
  43. Joseph JA, Cutler R, Roth GS. Changes in G protein-mediated signal transduction in aging and Alzheimer's disease. Ann. N.Y. Acad. Sci. 1993;695:42–45
  44. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, et al. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. U.S.A. 1996;93:6753–6758
  45. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 2004;25:186–192
  46. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001;24:219–224
  47. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 2006;59:13–20
  48. Li X, Greenwood AF, Powers R, Jope RS. Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Neurobiol. Aging. 1996;17:115–122
  49. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951;193:265–275
  50. Mattson MP, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int. J. Dev. Neurosci. 1998;16:737–753
  51. McLaughlin M, Ross BM, Milligan G, McCulloch J, Knowler JT. Robustness of G proteins in Alzheimer's disease: an immunoblot study. J. Neurochem. 1991;57:9–14
  52. Meier-Ruge W, Bertoni-Freddari C, Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology. 1994;40:246–252
  53. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav. Brain Res. 1996;75:1–11
  54. Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 2004;145:67–78
  55. Michal P, Lysikova M, Tucek S. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br. J. Pharmacol. 2001;132:1217–1228
  56. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304–307
  57. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 2006;23:563–572
  58. Pepeu G. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2001;25:193–209
  59. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 1977;34:247–265
  60. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977;1:189
  61. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 1977;83:346–356
  62. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 2000;20:2589–2601
  63. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005;18:602–617
  64. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741–766
  65. Sims NR, Bowen DM, Davison AN. [14C]Acetylcholine synthesis and carbon 14C dioxide production from [U-14C]glucose by tissue prisms from human neocortex. Biochem. J. 1981;196:867–876
  66. Snowdon DA. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 2003;139:450–454
  67. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, et al. Impaired coupling of muscarinic M(1) receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging. 2005;
  68. Tucek S, Michal P, Vlachova V. Modelling the consequences of receptor-G-protein promiscuity. Trends Pharmacol. Sci. 2002;23:171–176
  69. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka BK, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2006;
  70. Wang J, Tanila H, Puolivali J, Kadish I, van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 2003;14:318–327
  71. Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 1999;19:2706–2716
  72. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Exp. Ther. 2000;293:896–902

PII: S0197-4580(06)00402-7

doi: 10.1016/j.neurobiolaging.2006.10.029

Neurobiology of Aging
Volume 29, Issue 3 , Pages 368-378 , March 2008

Article Tools

* Image Usage & Resolution